Jagsonpal Pharmaceuticals Ltd vs Lasa Supergenerics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Apr 05, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 186.2 as of 02 Apr 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 yearsThe P/E Ratio of Lasa Supergenerics Ltd changed from 10.7 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 yearsThe Market Cap of Lasa Supergenerics Ltd changed from ₹ 243.63 crore on March 2021 to ₹ 84.42 crore on March 2025 . This represents a CAGR of -19.10% over 5 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Dec '25 is ₹ 75.92 crore as compare to the Sep '25 revenue of ₹ 77.49 crore. This represent the decline of -2.03% The revenue of Lasa Supergenerics Ltd for the Dec '25 is ₹ 2.22 crore as compare to the Sep '25 revenue of ₹ 3.07 crore. This represent the decline of -27.69% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Dec '25 is ₹ 17.16 crore as compare to the Sep '25 ebitda of ₹ 19.46 crore. This represent the decline of -11.82% The ebitda of Lasa Supergenerics Ltd for the Dec '25 is ₹ -0.73 crore as compare to the Sep '25 ebitda of ₹ -3.99 crore. This represent the decline of -81.7% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 10.95 crore over 7 quarters. This represents a CAGR of 50.90% The net profit of Lasa Supergenerics Ltd changed from ₹ -2.73 crore to ₹ -2.55 crore over 7 quarters. This represents a CAGR of -3.82% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Lasa Supergenerics Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Lasa Supergenerics Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,246 Cr while Market cap of Lasa Supergenerics Ltd is 31 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Lasa Supergenerics Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Lasa Supergenerics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Lasa Supergenerics Ltd?

As of April 5, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹186.2. On the other hand, Lasa Supergenerics Ltd stock price is INR ₹6.25.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Lasa Supergenerics Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Lasa Supergenerics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.